Skip to main content

Table 6 The result of scenario analysis (12-month treatment duration) over lifetime horizon

From: Cost-effectiveness analysis of combination therapies involving novel agents for first/second-relapse patients with multiple myeloma: a Markov model approach with calibration techniques

Strategies

LYs

QALY

Incremental QALY

Cost, ¥

Incremental Costs, ¥

ICER, ¥/QALY

Bortezomib Group

 Vd

3.72

2.23

Ref

747,026

Ref

Ref

 PVd

3.93

2.33

0.10

725,352

−21,674

A.D

 SVd

4.42

2.62

0.39

908,078

161,052

412,954

 DVd

4.97

2.93

0.70

1,022,211

275,185

393,121

 Kd

4.71

2.74

0.51

1,150,666

403,640

791,451

 PanVd

4.42

2.60

0.37

2,636,796

1,889,770

5,107,486

Lenalidomide Group

 Rd

4.83

2.82

Ref

783,318

Ref

Ref

 IxaRd

5.13

2.87

0.05

999,134

215,816

4,316,320

 KRd

5.37

3.17

0.35

1,049,942

266,624

761,783

 DRd

6.27

3.41

0.59

9,863,567

9,080,249

15,390,253

 ERd

5.74

3.09

0.27

1,673,607

890,289

3,297,367

Carfilzomib Group

 Kd

5.14

2.86

Ref

879,879

Ref

Ref

 DKd

6.29

3.44

0.58

1,348,696

468,817

808,305

 IsaKd

6.30

3.45

0.59

1,772,247

892,368

1,512,488

  1. Vd bortezomib-dexamethasone, Rd lenalidomide-dexamethasone, Kd carfilzomib-dexamethasone, DVd daratumumab-bortezomib-dexamethasone, SVd selinexor-bortezomib-dexamethasone, PVd pomalidomide-bortezomib-dexamethasone, PanVd pomalidomide-bortezomib-dexamethasone, ERd elotuzumab-lenalidomide-dexamethasone, DRd daratumumab-lenalidomide-dexamethasone, KRd carfilzomib-lenalidomide-dexamethasone, IxaRd ixazomib-lenalidomide-dexamethasone, Kd carfilzomib-dexamethasone, DKd daratumumab-carfilzomib-dexamethasone, IsaKd isatuximab-carfilzomib-dexamethasone, A.D. Absolute Dominant
Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us